LDLR Gene

Last updated on: 24.07.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

The LDLR gene (LDLR stands for "Low Density Lipoprotein Receptor") is a protein coding gene located on chromosome 19p13.2. Alternative splicing leads to several transcript variants.

General informationThis section has been translated automatically.

The low-density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. The encoded protein is normally bound to the cell membrane, where it binds low-density lipoprotein/cholesterol and is taken up into the cell. Lysosomes release the cholesterol available for repression of the microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, there is a reciprocal stimulation of cholesterol ester synthesis.

Mutations in this gene cause an autosomal dominant disorder, familial hypercholesterolemia.

LiteratureThis section has been translated automatically.

  1. Bertolini S et al. (2013) Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis 227:342-348.
  2. Stawowy P et al.(2014) PCSK9 as a new target in the therapy of hypercholesterolemia.Heart 39: 466-469.
  3. Zhao H et al. (2020) In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia. Circulation 141:67-79.

Last updated on: 24.07.2022